Sartorius Stedim Biotech SA banner

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 162.3 EUR 2.79% Market Closed
Market Cap: €15.8B

EV/S

5.8
Current
22%
Cheaper
vs 3-y average of 7.4

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
5.8
=
Enterprise Value
€17.3B
/
Revenue
€3B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
5.8
=
Enterprise Value
€17.3B
/
Revenue
€3B

Valuation Scenarios

Sartorius Stedim Biotech SA is trading below its 3-year average

If EV/S returns to its 3-Year Average (7.4), the stock would be worth €208.01 (28% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-75%
Maximum Upside
+34%
Average Upside
5%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 5.8 €162.3
0%
3-Year Average 7.4 €208.01
+28%
5-Year Average 7.8 €217.89
+34%
Industry Average 7.6 €213.7
+32%
Country Average 1.4 €40.31
-75%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
€17.3B
/
Apr 2026
€3B
=
5.8
Current
€17.3B
/
Dec 2026
€3.2B
=
5.4
Forward
€17.3B
/
Dec 2027
€3.6B
=
4.8
Forward
€17.3B
/
Dec 2028
€3.9B
=
4.4
Forward
€17.3B
/
Dec 2029
€4.4B
=
3.9
Forward
€17.3B
/
Dec 2030
€4.9B
=
3.5
Forward
€17.3B
/
Dec 2031
€5.9B
=
2.9
Forward
€17.3B
/
Dec 2032
€6.5B
=
2.7
Forward
€17.3B
/
Dec 2033
€7.2B
=
2.4
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
FR
Sartorius Stedim Biotech SA
PAR:DIM
15.8B EUR 5.8 58.9
US
PerkinElmer Inc
LSE:0KHE
1T USD 362.1 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
176.7B USD 4.5 26.4
US
Danaher Corp
NYSE:DHR
125.4B USD 5.5 34
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 17.9 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
298.9B CNY 5.8 15.6
CH
Lonza Group AG
SIX:LONN
34.3B CHF 5.5 -118.2
US
Agilent Technologies Inc
NYSE:A
32.7B USD 4.8 25.3
US
Waters Corp
NYSE:WAT
30.4B USD 9.7 47.3
US
IQVIA Holdings Inc
NYSE:IQV
27.5B USD 2.4 20.3
US
Mettler-Toledo International Inc
NYSE:MTD
26.1B USD 7 30

Market Distribution

Higher than 83% of companies in France
Percentile
83nd
Based on 1 736 companies
83nd percentile
5.8
Low
0 — 0.8
Typical Range
0.8 — 2.8
High
2.8 —
Distribution Statistics
France
Min 0
30th Percentile 0.8
Median 1.4
70th Percentile 2.8
Max 29 441 857.7

Sartorius Stedim Biotech SA
Glance View

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
138.44 EUR
Overvaluation 15%
Intrinsic Value
Price €162.3
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett